GlassScriptPhysician profile
Adam L Kruger
NPI 1568695831
$1,992.76
in general payments reported to CMS, 2019-2025
18 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $433 · 2022: $479 · 2023: $436 · 2024: $156 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $822.17 | 2021-2023 | Xience Sierra, Xience V |
| Pfizer INC. | $138.44 | 2019-2025 | |
| Angiodynamics, INC. | $133.56 | 2022 | |
| Boston Scientific Corporation | $129.03 | 2019-2024 | Sq-Rx Pulse Generator, Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $121.72 | 2019-2025 | |
| Tactile Systems Technology INC | $97.05 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $78.14 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $72.43 | 2021-2025 | Farxiga |
| Medtronic, INC. | $63.52 | 2021-2023 | Launcher |
| Amgen INC. | $62.80 | 2024-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.45 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $47.69 | 2019-2022 | |
| Novo Nordisk INC | $44.57 | 2024-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.29 | 2019-2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $23.73 | 2023 | Definity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.21 | 2021 | |
| Edwards Lifesciences Corporation | $19.09 | 2024 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $16.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kruger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.